As the only tertiary care medical center in Vermont, the University of Vermont Larner College of Medicine’s Division of Neurosurgery provides comprehensive surgical management of disorders of the brain, spinal cord and peripheral nervous system. Since the division's establishment in 1948, we have been committed to translating leading-edge research into improved patient care.

Residents

Medical students and neurosurgery residents participate in a variety of research activities and provide care and an array of treatment options for patients who have brain and spinal disease. By facilitating critical thinking, we advance the knowledge needed to treat neurologic disorders and enhance the quality of clinical care.


 

Academic and Clinical Excellence

Surgery

As physicians and scientists, the Division of Neurosurgery faculty brings intellectual curiosity, scientific rigor, and fundamental concern to our patients, our trainees, our colleagues, and the communities we serve in northern New England. 

We advance knowledge and innovation, and enhance efficiency through clinical, translational, and biomedical research studies designed to improve the care of patients with neurologic disease. We are dedicated to patient-and family-centric treatment of individuals with neurologic disease, and to developing the next generation of neurosurgical physicians. The UVM Neurosurgery Residency Program if fully accredited by ACGME and committed to training future leaders in the field to be outstanding clinicians, active investigators and experienced educators.


Surgery News

UVM Cancer Center Investigators Publish the Breast Pre-Cancer Atlas

January 18, 2022 by Kate Strotmeyer

UVM Cancer Center researchers contributed to the establishment of a breast pre-cancer atlas, which establishes the molecular and cellular properties of early-stage breast cancer and is the result of a six-year, National Cancer Institute-funded, collaborative initiative.

Gene expression in human breast cancer specimen analyzed by multi-spectral imaging.

As published in npj Breast Cancer, a Nature Portfolio publication, the pre-cancer atlas – a six-year, NCI-funded, collaborative initiative - establishes the molecular and cellular properties of early-stage breast cancer. By combining histological, molecular, and immunological profiling to provide risk markers for tumor progression, the groundbreaking research offers guidance for treatment or evidence-informed observation.

The paper, “The breast pre-cancer atlas illustrates the molecular and micro-environment diversity of ductal carcinoma in situ,” is co-authored by a team of six UVM Cancer Center investigators, Janet Stein, Ph.D., Donald Weaver, M.D., Gary Stein, Ph.D., Brian Sprague, Ph.D.,  Jonathan Gordon, Ph.D., and Mark Evans, Ph.D., who partnered with scientists and clinicians at the University of California San Francisco, the University of California Davis, and the University of California San Diego. 

Leveraging the power of recent methodological advances, the team characterized the mutational, transcriptional, histological, and micro-environment landscape of thirty-nine patient tumors to develop a multimodal breast pre-cancer atlas. 

The pre-cancer atlas combines parallel histological, molecular, and immunological profiling to provide risk markers for tumor progression and guidance for evidence-informed observation.

The breast pre-cancer atlas represents the expertise and experience of UVM Cancer Center scientists and physician investigators and the effective partnerships of cancer center members with colleagues who bring complimentary research and clinical capabilities. 

“The fabric of our Cancer Center is collaboration and the initiative reported in The breast pre-cancer atlas illustrates the molecular and micro-environment diversity of ductal carcinoma in situ illustrates a significant contribution that will be broadly relevant,” said Dr. Gary Stein, a co-investigator.